What is the appropriate treatment for purulent cellulitis in an adult without known drug allergies?

Treatment for Purulent Cellulitis

For purulent cellulitis in adults, empirical antibiotic therapy targeting CA-MRSA is recommended, with oral options including clindamycin (300-450 mg three times daily), TMP-SMX (1-2 double-strength tablets twice daily), or doxycycline (100 mg twice daily) for 5-10 days. 1

Key Distinction: Purulent vs. Nonpurulent

Purulent cellulitis is defined as cellulitis with purulent drainage or exudate in the absence of a drainable abscess. This distinction is critical because:

• Purulent cellulitis: CA-MRSA is the predominant pathogen; empirical streptococcal coverage is likely unnecessary 1
• Nonpurulent cellulitis: β-hemolytic streptococci are the primary concern; MRSA coverage only needed if patient fails β-lactam therapy 1

First-Line Antibiotic Options

Outpatient Oral Therapy (Mild to Moderate Disease)

The IDSA guidelines provide clear antibiotic choices with strength of evidence 1:

Single-agent options (MRSA coverage only):

• Clindamycin 300-450 mg PO three times daily (A-II evidence)

  • Covers both CA-MRSA and streptococci
  • Caution: Higher risk of C. difficile infection

• TMP-SMX 1-2 double-strength tablets PO twice daily (A-II evidence)

  • Excellent CA-MRSA coverage (95-100% susceptibility)
  • Does NOT cover streptococci reliably
  • Contraindicated in third trimester pregnancy and infants <2 months
  • Risk of hyperkalemia in elderly, especially with renal insufficiency or ACE inhibitors 1

• Doxycycline 100 mg PO twice daily (A-II evidence)

  • Good MRSA coverage
  • Does NOT cover streptococci reliably
  • Contraindicated in children <8 years and pregnancy (category D) 1

• Linezolid 600 mg PO twice daily (A-II evidence)

  • Covers both MRSA and streptococci
  • Most expensive option; reserve for specific situations 1

When to Add Streptococcal Coverage

If you want dual coverage for both CA-MRSA and β-hemolytic streptococci (though guidelines suggest this is likely unnecessary for purulent cellulitis):

• Clindamycin alone (covers both) 1
• TMP-SMX or doxycycline PLUS amoxicillin 500 mg three times daily 1
• Linezolid alone (covers both) 1

Duration of Therapy

5-10 days is recommended, individualized based on clinical response 1. The 2014 IDSA guidelines specifically recommend 5 days minimum, extending only if infection has not improved 2.

Hospitalization Criteria

Admit for IV therapy if patient has:

• Systemic inflammatory response syndrome (SIRS)
• Hemodynamic instability
• Altered mental status
• Concern for deeper/necrotizing infection
• Severe immunocompromise
• Poor adherence anticipated 2

Inpatient IV Options (Complicated SSTI)

For hospitalized patients requiring parenteral therapy 1:

• Vancomycin 15-20 mg/kg/dose IV every 8-12 hours (A-I evidence)
• Linezolid 600 mg IV/PO twice daily (A-I evidence)
• Daptomycin 4 mg/kg IV once daily (A-I evidence)
• Clindamycin 600 mg IV/PO three times daily (A-III evidence)

Duration: 7-14 days for complicated infections 1

Critical Pitfalls to Avoid

1. Do NOT use rifampin as monotherapy or adjunctive therapy for SSTI—no benefit demonstrated 1

2. Cultures are NOT routinely recommended for typical purulent cellulitis unless:

   • Patient has malignancy/chemotherapy
   • Neutropenia present
   • Severe immunodeficiency
   • Immersion injury or animal bite 2

3. If drainable abscess is present, incision and drainage is PRIMARY treatment; antibiotics are adjunctive only if:

   • Severe/extensive disease
   • Multiple sites
   • Systemic symptoms
   • Comorbidities/immunosuppression
   • Extremes of age
   • Difficult drainage location (face, hand, genitalia)
   • Failed I&D alone 1

4. Bilateral cellulitis is rare—consider alternative diagnoses like venous stasis dermatitis 3

5. Examine interdigital toe spaces for tinea pedis, as treating this reduces recurrence risk 2

Adjunctive Measures

• Elevate affected extremity 2
• Treat predisposing factors: edema, tinea pedis, skin fissures 2
• Consider decolonization for recurrent infections (intranasal mupirocin, chlorhexidine washes) 2

Evidence Quality Note

The 2011 IDSA MRSA guidelines 1 provide the most specific recommendations for purulent cellulitis with high-quality evidence (A-I to A-II ratings). The 2014 general SSTI guidelines 2 are also authoritative but less specific for the purulent subtype. Real-world data from Hawaii 4 showed TMP-SMX had 91% success rate vs. 74% for cephalexin in MRSA-prevalent areas, supporting guideline recommendations.